Sabin Vaccine Institute Receives $35 Million from BARDA with Potential of up to $214 Million for Ebola Sudan and Marburg Vaccines
Sabin Vaccine Institute Awarded BARDA Contract With Funding Potential up to $214M for Ebola Sudan and Marburg Vaccines
The Sabin Vaccine Institute will produce up to 100,000 doses of Sabin’s Ebola Sudan vaccine as part of a new, multi-year contract with BARDA
WASHINGTON, Jan. 12, 2023 (GLOBE NEWSWIRE) — The Sabin Vaccine Institute today announced that the Biomedical Advanced Research and Development Authority (BARDA) has awarded Sabin a multi-year contract with funding potential for up to $214 million to advance the development and production of single-dose vaccine candidates for Ebola Sudan and Marburg virus diseases.
There are currently no licensed vaccines against Ebola Sudan and Marburg viruses, which cause hemorrhagic fever and kill approximately half the people infecte...